Pipeline
PIPELINE OVERVIEW
A focused portfolio built on targeting disease-driving macrophage populations in patients most likely to benefit.
Lead CD163 programs
Discovery platform
Program
Description
Indication
Target
Discovery
Preclinical
IND-enabling
Phase 1
Lead program
CD163
Solid tumors
Lead program
CD163
Fibrosis
Additional programsPlatform expansion
Macrophage fingerprint platform
Multiple
ONCOLOGY
TME remodelling to sensitize patients to immunotherapy-mediated tumor killing.
Focused on depletion of CD163+ tumor-associated macrophages, increased T cell activation and potentiation of immunotherapy-mediated killing.
FIBROSIS
Slowing or halting fibrosis through macrophage-to-myofibroblast transition biology.
Designed around depletion of pro-fibrotic macrophage populations and translational fibrosis models.
PATIENT SELECTION
CD163 antibody tracer to support selection and treatment monitoring.
A translational companion concept for stratification and response insight across both lead programs.